FDA rejects two drugs over single-country data and integrity issues; China opens mAb tender
Summary
The episode examines whether trial data from a single country is sufficient for FDA approval, citing two recent rejections. One rejection involved CMG901, an antibody-drug conjugate licensed to AstraZeneca, while another concerned Capricor's deramiocel due to data integrity violations. The hosts discuss precedents like Innovent's sintilimab and Junshi's toripalimab to illustrate the FDA's criteria for non-US data. Additionally, China's National Healthcare Insurance Administration has opened filings for a national monoclonal antibody tender covering seven antibodies.
Key takeaways
Episode sections
- 0:04 – 0:40
Opening: Is one country's data enough?
The episode opens by noting two recent FDA rejections: one for a cancer drug with key results from China, and another for a cell therapy due to data reliability concerns. It poses the question of whether trial data from a single country is sufficient for FDA approval.
- 0:40 – 2:14
A China-born drug gets a faster review
The FDA accepted a priority review application for CMG901 (sonesitatug vedotin), an antibody-drug conjugate from KeyMed and Lepu Biopharma licensed to AstraZeneca. The drug targets Claudin 18.2-positive advanced stomach and esophageal cancers, with a decision expected in Q2 2027.
- 2:14 – 6:22
Is single-country data enough? Precedents
The hosts analyze three precedents for FDA acceptance of non-US data: the 2022 rejection of Innovent's sintilimab (China-only data), the 2023 approval of Junshi's toripalimab (Asian data), and Roche's 2025 rejection of Columvi (only 9% US patients). The dividing line appears to be applicability to US patients and survival endpoints.
- 6:22 – 8:45
Data integrity issues: Capricor's deramiocel
The FDA issued a complete response letter for Capricor's deramiocel, citing serious data integrity violations in the HOPE-3 trial, including unauthorized changes to the statistical analysis plan and blinding violations. Capricor disputes these claims, maintaining their data is rigorous.
- 8:45 – 10:50
China's national antibody tender
China's National Healthcare Insurance Administration opened filings for a national monoclonal antibody tender, covering seven antibodies in 15 strengths. The tender allows both original brands and biosimilars to bid, with strict manufacturing and GMP requirements.
Claims worth verifying
Decision for CMG901 is expected in the second quarter of 2027.
Ning ·0:59
How to verify: FDA PDUFA date listed in the FDA approval letter or press release for the NDA. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
CMG901 is developed by KeyMed Biosciences and Lepu Biopharma, licensed worldwide to AstraZeneca in 2023.
Ning ·1:08
How to verify: AstraZeneca press release or SEC filing (if public) detailing the license agreement; company websites for KeyMed and Lepu. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
Primary sourceCMG901 trial involved 175 centers in 19 countries across North America, Europe, South America, and Asia.
Unidentified speaker (UNKNOWN) ·1:29
How to verify: ClinicalTrials.gov record for the CMG901 trial; AstraZeneca clinical data summary. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
AstraZeneca claims CMG901 cut the risk of death by 42% compared with standard options.
Unidentified speaker (UNKNOWN) ·1:29
How to verify: AstraZeneca press release or clinical publication reporting the hazard ratio for overall survival. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
Survival in patients on third treatment or later showed a 53% lower risk of death; progression-free survival did not reach statistical significance.
Ning ·1:44
How to verify: AstraZeneca clinical data summary or OncLife report cited by the podcast; peer-reviewed publication of trial results. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
In February 2022, an FDA advisory committee voted 14 to 1 for more data on sintilimab; complete response letter issued in March 2022.
Ning ·2:26
How to verify: FDA advisory committee meeting minutes and summary actions; Innovent Biologics press release or FDA correspondence regarding sintilimab. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
Toripalimab was approved based on trials run in Asia, including China, Taiwan, and Singapore, with 289 patients in the main trial.
Unidentified speaker (speaker_0) ·3:26
How to verify: FDA approval letter for toripalimab; Shanghai Junshi Biosciences press release; clinical trial records for Jupiter-02. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
Roche received a complete response letter for Columvi in July 2025; only 9% of trial patients were in the US.
Ning ·4:21
How to verify: Roche press release or FDA correspondence regarding Columvi; clinical trial demographics for the StarGlow trial. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
FDA cited serious data integrity violations in Capricor's HOPE-3 trial, including unauthorized post hoc changes to the statistical analysis plan and violations of study blinding.
Ning ·6:43
How to verify: FDA complete response letter to Capricor Therapeutics; Capricor press release responding to the FDA letter. For recent events, verify 2026-08-22 through 2026-11-22. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Review FDA Priority Review designations for CMG901 and check AstraZeneca's pipeline updates.
- Examine the complete response letter for Capricor's deramiocel to understand specific data integrity allegations.
- Compare the clinical trial designs and patient demographics of Innovent's sintilimab vs. Junshi's toripalimab to assess FDA criteria for non-US data.
- Check China's National Healthcare Insurance Administration website for the latest tender documents and participating companies.
- Verify Capricor's public statements and dispute letters regarding the HOPE-3 trial violations.
- Analyze historical FDA approval rates for drugs relying solely on non-US data.
- Look for conflicts of interest or financial ties between KeyMed, Lepu Biopharma, and AstraZeneca.
- Review Roche's public statements regarding the Columvi rejection and its implications for global trial design.
Full transcriptexpand
0:04Unidentified speaker (UNKNOWN): This
0:05Unidentified speaker (speaker_0): month the FDA said no twice to a cancer drug whose key results came mostly from China and to a cell therapy over whether its data could be relied on. So, is one country's data enough?
0:17Unidentified speaker (UNKNOWN): I'm
0:17Unidentified speaker (speaker_0): Basil Louis, investing globally from Singapore with an Asia angle. This is the East West Biobrief, Biotech and Beyond for Sunday, 22 November.
0:26Unidentified speaker (UNKNOWN): And
0:27Ning: I'm Ning, Basil's AI co-host. Both our voices are AI clones, but Basil is the real person behind this show. Personal views, not investment advice. First, a fresh test case. On Thursday, the FDA accepted, with priority review, an and application for Sona sonar Citatok citatovedotin, Vedotin, also known as CMG. CMG901. It's for advanced stomach and osophageal cancers whose tumors carry a protein called Claudin 18.2 in patients who've already had at least one treatment. A decision is expected in the second quarter of 2027.
1:07Unidentified speaker (UNKNOWN): And
1:07Unidentified speaker (speaker_0): where did it come from?
1:08Ning: From KMET Key Met Biosciences in Chinese Kanoya Kangoya, and Lepu Biopharma in China. Chinese, Yuepu Seng U. The joint venture licensed it worldwide to AstraZeneca in 2023. It's an antibody drug conjugate, an antibody that fines chlodine 18.2 on cancer cells and delivers a chemotherapy payload.
1:29Unidentified speaker (UNKNOWN): The
1:29Unidentified speaker (speaker_0): trial behind the filing was global by design. 175 75 centers in 19 countries across North America, Europe, South America, and Asia. AstraZeneca says the drug cut the risk of death by 42% compared with standard options.
1:44Ning: Two caveats. That 42% was a key secondary goal. Of the two main goals, survival in patients on their third treatment or later was met with a 53% lower risk of death, according to KeyMed. Progression-free survival across all patients did not reach statistical. significance in the Congress data reported by OncLife. And priority review is a faster timetable, not an approval.
2:13Unidentified speaker (speaker_0): That global design is the threat for today's feature from our running theme: Where Do the Patients Come From? The question is trial data from one country or one region enough for the FD3 precedents?
2:26Ning: President 1, 2022, Cintilimab, an immune drug from Innovant Biologics in Chinese Xin Da Shengwu, partnered with Eli Lili, was filed for first-line lung cancer on one trial, Orient 11, run entirely in China, with 397 patients. In February, an FDA advisory committee voted 14 to 1 for more data. first. In March came a complete response letter. The issue wasn't whether the drug worked in that trial. FDA reviewers said foreign data must apply to US patients and US medical practice. They cited a single country population, a comparison arm that wasn't US standard care, progression-free progression free survival rather than overall survival as the main goal. and no FDA consultation until the trial was done. The letter asked for a multi-regional trial with a survival endpoint.
3:26Unidentified speaker (speaker_0): The FDA approved Tori Polymap developed by Shanghai Junxi Biosciences for nasopharyngeal cancer, a cancer behind the nose. Both supporting trials were run in Asia. The main one, Jupiter. 0 2, enrolled 289 patients at 35 centers in mainland China, Taiwan, and Singapore.
3:46Unidentified speaker (UNKNOWN): So
3:46Ning: why did Asian data count that time?
3:49Unidentified speaker (UNKNOWN): The
3:49Unidentified speaker (speaker_0): FDA's notice doesn't rank its reasons, but three differences stand out.
3:55Unidentified speaker (UNKNOWN): The
3:55Unidentified speaker (speaker_0): disease is much more common in southern China and Southeast Asia than in the US, so that's where the patients are. It became the first immunotherapy. approved for this cancer in the US.
4:05Unidentified speaker (UNKNOWN): And
4:06Unidentified speaker (speaker_0): the main trial showed patients lived longer overall, not just longer without progression. One view from Singapore Singapore was one of the three places that trial enrolled patients.
4:21Ning: Companies. In July 2025, Roche, the Swiss drug maker, got a complete response letter for its lymphoma drug Columvi with chemotherapy. Its Star Glow trial met its main survival goal. But only 25 of 274 patients, 9%, were in the US and 48% were enrolled in Asia.
4:41Unidentified speaker (UNKNOWN): Is
4:41Unidentified speaker (speaker_0): that the same objection as Cynthia Lima?
4:44Ning: Close to it, an FDA advisory committee voted 8 to 1 that the results weren't applicable. to US patients. Members cited few US patients, results that differed between Asian and non-Asian patients, and not following ICHE 17, the international guideline for multi-regional trials. At the time, Raj noted the combination was approved in more than 35 countries, including in the EU.
5:12Unidentified speaker (speaker_0): And the same yardstick came up this week. As we reported on Thursday, the FDA's letter on Ivones Kimap from AkeSo in Chinese Kang Fang Seng Wu said 93% of the trials progression events were in patients enroll in China and asked for a new multi-regional trial consistent with ICHE 17.
5:35Unidentified speaker (UNKNOWN): So
5:36Unidentified speaker (speaker_0): on these precedents, the dividing line isn't. east versus west. Data from one country or region has counted when the disease, the patients, and the comparison match US use and survival holds up. It has fallen short when reviewers doubted the results applied to US patients. That's why CMG 901's 19 country design is worth watching.
5:59Ning: One line for our AI drug race thread. Whose patients train the AI? On November 12th, the FDA said sponsors frequently don't own the real-world data used in their studies, so they may lack authorization to submit patient-level records. It's asking for ideas. With comments due by January 11th, that's a request for information, not a new rule.
6:22Unidentified speaker (speaker_0): Where patients come from is one test. Whether the data can be relied on. is another. On Friday, U.S. Time, the FDA issued a complete response letter for D. Ramiol, a cell therapy from Capricor Therapeutics in San Diego for Duchenne muscular dystrophy and inherited muscle wasting disease that mainly affects boys.
6:43Ning: In an unusual public statement, the FDA said its correspondence identifies serious data integrity violations. in the key HOPE 3 trial. In its words, they include unauthorized post hoc changes to the statistical analysis plan, violations of study blinding procedures, and additional protocol violations. It says these cannot be fixed after the fact and that HOPE 3 failed its pre-specified primary and secondary endpoints.
7:13Unidentified speaker (speaker_0): Capricor disputes that. Its chief executive, Linda Marban, said Hope 2 and Hope 3 both met their primary endpoints and we stand behind the rigor of our clinical program and the integrity of our data. The company says it's reviewing the letter and has a call on Monday at 8 30 a.m. Eastern, 9 30 pm Singapore time.
7:34Ning: Basil, Biopharma BiopharmaDive Dive notes the FDA has signaled. more flexibility on rare diseases. Does the statement address that?
7:43Unidentified speaker (speaker_0): It does. The FDA says it approaches rare disease applications with every intention of finding a path forward, but that flexibility cannot come at the cost of the foundational requirement that the data underlying an approval decision be reliable. BiopharmaDive reports that more than two dozen trial investigators and physicians had written in support of approval.
8:06Ning: There's an East-West threat too. Nippon Shinyaku of Japan is Capricor's exclusive distributor for D-Rameo cell in the US under a 2022 agreement. And in Japan, under a 2023 deal with a $12 million upfront payment. Capricor says the two companies are in arbitration over the U.S. agreement, with a hearing expected to begin in mid 2027.
8:31Unidentified speaker (speaker_0): These are two accounts of one decision, and we're not picking between them. Deram Young Cell is investigational and not approved. We'll see what Capricorne says on Monday.
8:45Ning: Saturday, China's National Alliance tender for monoclonal antibodies published its first notice, opening the filing process. It's part of the volume-based buying system known in Chinese as Jitai. Xinhua's Economic Information Daily calls it the largest antibody alliance tender in China so far. Seven antibodies in 15 strengths, including adalimumap, bevacizo map, rituximab, and trastuzomap, used in cancer and autoimmune disease.
9:13Unidentified speaker (speaker_0): The rules are built for biologics. Original brands and biosimilars can both bid, including foreign license holders, through a local responsible party. Bidders need at least two years of antibody manufacturing records, clean GMP inspections, and a written commitment that their product doesn't infringe patterns. Products that can't give it and are already listed on provincial platforms will be taken off. Filing runs Tuesday to Friday. Price cuts won't be known until the bidding. So back to the title. Is one country's data enough? On these precedents, sometimes when reviewers are satisfied it applies to US patients and US practice, and when survival holds up.
9:55Unidentified speaker (UNKNOWN): The
9:55Unidentified speaker (speaker_0): two notes this month had different reasons, where the patients were and whether the data can be relied on. Watch for Capricor's Capricorse call on. Monday, the antibody tender filings this week, and the FDA's decision on CMG 901, expected in the second quarter of 2027. I have no personal holding in any of the companies mentioned today. If this brief is useful, follow the East West Biobrief Bio brief on Spotify or Apple Podcasts.
10:24Ning: And for the transcripts and sources, subscribe. to our newsletter on LinkedIn, also called the East West Bio Brief. It goes out every Monday with our weekly roundup. That's today's brief. The key sources are in the show notes. See you tomorrow for our weekly.